|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network.
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Freed-Pastor WA and Prives C: Mutant p53:
one name, many proteins. Genes Dev. 26:1268–1286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brachova P, Thiel KW and Leslie KK: The
consequence of oncomorphic TP53 mutations in ovarian cancer. Int J
Mol Sci. 14:19257–19275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hall J, Paul J and Brown R: Critical
evaluation of p53 as a prognostic marker in ovarian cancer. Expert
Rev Mol Med. 6:1–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meng X, Dizon DS, Yang S, et al:
Strategies for molecularly enhanced chemotherapy to achieve
synthetic lethality in endometrial tumors with mutant p53. Obstet
Gynecol Int. 2013:8281652013. View Article : Google Scholar
|
|
9
|
Meng X, Laidler LL, Kosmacek EA, et al:
Induction of mitotic cell death by overriding G2/M checkpoint in
endometrial cancer cells with non-functional p53. Gynecol Oncol.
128:461–469. 2013. View Article : Google Scholar :
|
|
10
|
Hanel W, Marchenko N, Xu S, Xiaofeng Yu S,
Weng W and Moll U: Two hot spot mutant p53 mouse models display
differential gain of function in tumorigenesis. Cell Death Differ.
20:898–909. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gaiddon C, Lokshin M, Ahn J, Zhang T and
Prives C: A subset of tumor-derived mutant forms of p53
down-regulate p63 and p73 through a direct interaction with the p53
core domain. Mol Cell Biol. 21:1874–1887. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie TX, Zhou G, Zhao M, et al: Serine
substitution of proline at codon 151 of TP53 confers gain of
function activity leading to anoikis resistance and tumor
progression of head and neck cancer cells. Laryngoscope.
123:1416–1423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scian MJ, Stagliano KE, Deb D, et al:
Tumor-derived p53 mutants induce oncogenesis by transactivating
growth-promoting genes. Oncogene. 23:4430–4443. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lang GA, Iwakuma T, Suh YA, et al: Gain of
function of a p53 hot spot mutation in a mouse model of Li-Fraumeni
syndrome. Cell. 119:861–872. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Olive KP, Tuveson DA, Ruhe ZC, et al:
Mutant p53 gain of function in two mouse models of Li-Fraumeni
syndrome. Cell. 119:847–860. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang YX and Kotlikoff MI: Inactivation of
calcium-activated chloride channels in smooth muscle by
calcium/calmodulin-dependent protein kinase. Proc Natl Acad Sci
USA. 94:14918–14923. 1997. View Article : Google Scholar
|
|
17
|
Ko JL, Chiao MC, Chang SL, et al: A novel
p53 mutant retained functional activity in lung carcinomas. DNA
Repair (Amst). 1:755–762. 2002. View Article : Google Scholar
|
|
18
|
Sproston AR, Boyle JM, Heighway J, Birch
JM and Scott D: Fibroblasts from Li-Fraumeni patients are resistant
to low dose-rate irradiation. Int J Radiat Biol. 70:145–150. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song H, Hollstein M and Xu Y: p53
gain-of-function cancer mutants induce genetic instability by
inactivating ATM. Nat Cell Biol. 9:573–580. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krepulat F, Löhler J, Heinlein C,
Hermannstädter A, Tolstonog GV and Deppert W: Epigenetic mechanisms
affect mutant p53 transgene expression in WAP-mutp53 transgenic
mice. Oncogene. 24:4645–4659. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bergamaschi D, Gasco M, Hiller L, et al:
p53 polymorphism influences response in cancer chemotherapy via
modulation of p73-dependent apoptosis. Cancer cell. 3:387–402.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Irwin MS, Kondo K, Marin MC, Cheng LS,
Hahn WC and Kaelin WG Jr: Chemosensitivity linked to p73 function.
Cancer cell. 3:403–410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duan W, Ding H, Subler MA, et al:
Lung-specific expression of human mutant p53-273H is associated
with a high frequency of lung adenocarcinoma in transgenic mice.
Oncogene. 21:7831–7838. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morselli E, Tasdemir E, Maiuri MC, et al:
Mutant p53 protein localized in the cytoplasm inhibits autophagy.
Cell cycle. 7:3056–3061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bourdon JC, Fernandes K, Murray-Zmijewski
F, et al: p53 isoforms can regulate p53 transcriptional activity.
Genes Dev. 19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hofstetter G, Berger A, Fiegl H, et al:
Alternative splicing of p53 and p73: the novel p53 splice variant
p53delta is an independent prognostic marker in ovarian cancer.
Oncogene. 29:1997–2004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Holmila R, Fouquet C, Cadranel J, Zalcman
G and Soussi T: Splice mutations in the p53 gene: case report and
review of the literature. Hum Mutat. 21:101–102. 2003. View Article : Google Scholar
|
|
28
|
Sameshima Y, Akiyama T, Mori N, et al:
Point mutation of the p53 gene resulting in splicing inhibition in
small cell lung carcinoma. Biochem Biophys Res Commun. 173:697–703.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bodnar L, Stanczak A, Cierniak S, et al:
Wnt/β-catenin pathway as a potential prognostic and predictive
marker in patients with advanced ovarian cancer. J Ovarian Res.
7:162014. View Article : Google Scholar
|
|
30
|
Kang HJ, Chun SM, Kim KR, Sohn I and Sung
CO: Clinical relevance of gain-of-function mutations of p53 in
high-grade serous ovarian carcinoma. PloS One. 8:e726092013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monti P, Campomenosi P, Ciribilli Y, et
al: Characterization of the p53 mutants ability to inhibit p73 beta
transactivation using a yeast-based functional assay. Oncogene.
22:5252–5260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu G, McDonnell TJ, Montes de Oca Luna R,
et al: High metastatic potential in mice inheriting a targeted p53
missense mutation. Proc Natl Acad Sci USA. 97:4174–4179. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rose SL, Goodheart MJ, DeYoung BR, Smith
BJ and Buller RE: p21 expression predicts outcome in p53-null
ovarian carcinoma. Clin Cancer Res. 9:1028–1032. 2003.PubMed/NCBI
|
|
34
|
Schmider A, Gee C, Friedmann W, et al: p21
(WAF1/CIP1) protein expression is associated with prolonged
survival but not with p53 expression in epithelial ovarian
carcinoma. Gynecol Oncol. 77:237–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rojas M, Yao S and Lin YZ: Controlling
epidermal growth factor (EGF)-stimulated Ras activation in intact
cells by a cell-permeable peptide mimicking phosphorylated EGF
receptor. J Biol Chem. 271:27456–27461. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ludes-Meyers JH, Subler MA, Shivakumar CV,
et al: Transcriptional activation of the human epidermal growth
factor receptor promoter by human p53. Mol Cell Biol. 16:6009–6019.
1996.PubMed/NCBI
|
|
37
|
Di Agostino S, Strano S, Emiliozzi V, et
al: Gain of function of mutant p53: the mutant p53/NF-Y protein
complex reveals an aberrant transcriptional mechanism of cell cycle
regulation. Cancer cell. 10:191–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong KK, Izaguirre DI, Kwan SY, et al:
Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol.
130:565–569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Willis A, Jung EJ, Wakefield T and Chen X:
Mutant p53 exerts a dominant negative effect by preventing
wild-type p53 from binding to the promoter of its target genes.
Oncogene. 23:2330–2338. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu J, Qian J, Hu Y, et al: Heterogeneity
of Li-Fraumeni syndrome links to unequal gain-of-function effects
of p53 mutations. Sci Rep. 4:42232014.PubMed/NCBI
|
